Intervention

Irinotecan

ClinicalTrials.gov intervention label

Clinical trials47
Recruiting6
Common conditions25
Lead sponsors shown15

Clinical trials

47 shown
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)NCT07155200 · 2025-12-18
RECRUITING
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerNCT06954246 · 2025-06-04
RECRUITING
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCNCT06496048 · 2024-09-14
RECRUITING
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsNCT06586515 · 2024-09-12
RECRUITING
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16
RECRUITING
Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · 2023-02-22
RECRUITING
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsNCT06607185 · 2024-10-21
ACTIVE_NOT_RECRUITING
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)NCT05049863 · 2023-02-27
TERMINATED
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)NCT05731518 · 2023-02-23
UNKNOWN
SMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWN
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung CancerNCT05595889 · 2022-12-01
UNKNOWN
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27
COMPLETED
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)NCT05153239 · 2022-07-22
COMPLETED
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)NCT05239741 · 2022-04-02
ACTIVE_NOT_RECRUITING
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st ChemotherapyNCT04985201 · 2021-11-01
UNKNOWN
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）NCT04453930 · 2020-06-08
UNKNOWN
9-ING-41 in Patients With Advanced CancersNCT03678883 · 2019-01-04
ACTIVE_NOT_RECRUITING
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung CancerNCT03651219 · 2018-09-08
UNKNOWN
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)NCT03374254 · 2018-02-16
COMPLETED
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerNCT03098030 · 2017-06-01
COMPLETED
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable CancerNCT03009058 · 2017-05-31
TERMINATED
Irinotecan for Advanced and Metastatic Breast CancerNCT03562390 · 2017-04-01
UNKNOWN
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)NCT02720068 · 2016-05-02
COMPLETED
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)NCT02489903 · 2015-06-01
COMPLETED
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)NCT02423954 · 2015-04-01
TERMINATED
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung CancerNCT02348450 · 2015-02-01
UNKNOWN
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)NCT02331251 · 2014-12-01
TERMINATED
Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLCNCT02275806 · 2014-10-01
TERMINATED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer PatientsNCT01941316 · 2013-11-01
COMPLETED
A Protocol of Irinotecan for Carcinoma of the LungNCT01654081 · 2013-10-01
WITHDRAWN
Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung CancerNCT01977235 · 2013-09-01
UNKNOWN
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid TumorsNCT01803282 · 2013-03-29
COMPLETED
Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung CancerNCT01635400 · 2012-06-01
UNKNOWN
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung CancerNCT01607554 · 2012-04-01
TERMINATED
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersNCT01451632 · 2011-10-01
COMPLETED
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)NCT00874328 · 2008-10-01
UNKNOWN
RSHF in Colorectal CancerNCT01220063 · 2007-10-19
COMPLETED
Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IVNCT00614965 · 2006-11-01
COMPLETED
Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)NCT00452634 · 2006-04-01
COMPLETED
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLCNCT00319800 · 2006-02-01
UNKNOWN
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung CancerNCT00057837 · 2004-07-14
COMPLETED
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and CapecitabineNCT00072852 · 2003-11-01
COMPLETED
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung CancerNCT00193375 · 2003-08-01
COMPLETED
Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung CancerNCT00264134 · 2003-06-01
TERMINATED
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung CancerNCT00139711 · 2003-03-01
COMPLETED
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung CancerNCT00193349 · 2002-09-01
COMPLETED
Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung CancerNCT00819728 · 2000-06-01
COMPLETED

Common conditions

Small Cell Lung Cancer9Non-small Cell Lung Cancer7Small Cell Lung Carcinoma5Colorectal Cancer4Lung Cancer4Pancreatic Cancer4Breast Cancer3Carcinoma, Non-Small-Cell Lung3Non Small Cell Lung Cancer3Small-cell Lung Cancer3Advanced Cancer2Breast Neoplasms2Metastatic Colorectal Cancer2Pancreatic Ductal Adenocarcinoma2Relapsed Small Cell Lung Cancer2Sarcoma2Acute T Cell Leukemia Lymphoma1Advanced Breast Carcinoma1Advanced Malignant Solid Neoplasm1Advanced Non-Small Cell Lung Cancer1Advanced Ovarian Carcinoma1Advanced Pancreatic Carcinoma1Advanced Prostate Carcinoma1Advanced Sarcoma1Advanced Solid Tumor1

Trial status mix

COMPLETED18
UNKNOWN11
TERMINATED7
RECRUITING6
ACTIVE_NOT_RECRUITING3
WITHDRAWN2

Phase mix

PHASE233
PHASE118
PHASE36
EARLY_PHASE11
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.